What's Happening?
Expression Therapeutics, Inc., a clinical-stage gene and cell therapy company, has received a Phase II Small Business Innovation Research (SBIR) grant of $2,058,885 from the National Cancer Institute (NCI) within the National Institutes of Health (NIH).
This grant will fund the advancement of ET501, an investigational PTK7-targeted γδ (gamma delta) T-cell therapy designed for children with high-risk neuroblastoma. The two-year award will support activities aimed at preparing an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). Neuroblastoma is a rare pediatric cancer, with over 650 cases diagnosed annually in the U.S., and current five-year event-free survival rates for high-risk disease are 51.2%. ET501 utilizes the company's ADEPT-STAR platform to engineer γδ T cells that secrete a T-cell engager at the tumor site, targeting the PTK7 protein on neuroblastoma cells.
Why It's Important?
This NCI SBIR grant is crucial for advancing a potential new treatment option for children suffering from high-risk neuroblastoma, a disease with significant unmet medical needs and challenging survival rates. The development of ET501 represents an innovative approach to cancer therapy by leveraging γδ T cells, which can recognize stressed and cancerous cells without requiring a tissue-type match. By secreting a PTK7xCD3 engager directly within the tumor, ET501 aims to recruit both the infused γδ T cells and existing T cells to mount a stronger, more targeted attack against cancer cells. This funding not only supports the progression of ET501 towards human clinical trials but also validates Expression Therapeutics' γδ T-cell platform, which has applications for other cancers like neuroendocrine tumors.
What's Next?
The immediate next step for Expression Therapeutics is to utilize the NCI SBIR grant to conduct the necessary studies and activities required for submitting an Investigational New Drug (IND) application to the FDA. This will involve preclinical research to demonstrate the safety and efficacy of ET501, ensuring it performs as intended and meets regulatory requirements for human testing. If the IND application is approved, the company will proceed with clinical trials to evaluate ET501 in children with high-risk neuroblastoma. The grant also supports the advancement of ET401, another γδ T-cell therapy for adults with neuroendocrine tumors, indicating a broader impact on the company's pipeline and future therapeutic developments.
Beyond the Headlines
The development of ET501 highlights the growing potential of cell and gene therapies in treating complex diseases, particularly rare pediatric cancers where conventional treatments may be limited. This approach, which engineers immune cells to specifically target and attack cancer, represents a paradigm shift in oncology, moving towards more personalized and less toxic treatments. The success of such therapies could not only improve survival rates but also enhance the quality of life for young patients. Furthermore, the NIH's investment through the SBIR program underscores the government's commitment to fostering innovation in small businesses to address critical health challenges, potentially accelerating the translation of cutting-edge research into clinical practice and offering hope to families facing devastating diagnoses.
